Continuous or Limited-Duration Venetoclax Plus Rituximab for Relapsed CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy
Blood 2021 Sep 09;138(10)836-846, S Ma, JF Seymour, DM Brander, TJ Kipps, MY Choi, MA Anderson, K Humphrey, A Al Masud, J Pesko, R Nandam, AH Salem, B Chyla, J Arzt, A Jacobson, SY Kim, AW RobertsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.